This CPB is revised to state that eliglustat for children and adolescents less than 18 years of age who are diagnosed with Type 1 Gaucher disease is considered medically necessary if the member is a CYP2D6 extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM). This CPB is revised to state that eliglustat is considered experimental and investigational for Type 3 Gaucher disease because its effectiveness for this indication has not been established.